All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-06-06T12:01:41.000Z

EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?

By Marta Llobet-Canela, Jennifer Higgins
Jun 6, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Top abstracts in multiple myeloma and other plasma cell dyscrasias

S100

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma

Hermann Einsele

S190

First results from the REDIRECTT-1 study with teclistamab (TEC) + talquetamab (TAL) simultaneously targeting BCAM and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Maria-Victoria Mateos 

S192

Talquetamab (TAL) + daratumumab (DARA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results

Nizar J Bahlis

S195

Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KARMMA-3 analysis in high-risk subgroups

Krina Patel

S197

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma

Hans C Lee

S199

A phase 3, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma (DREAMM-3)

Meletios Dimopoulos

S202

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

Nikhil Munshi

S203

Quadruplet induction therapy, ASCT and MRD-modulated consolidation and treatment cessation in newly diagnosed multiple myeloma: Final analysis of the MASTER trial

Luciano Costa

S204

Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study

Jason Valent

P870

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MAGNETISMM studies

Salomon Manier

Top abstracts by region

In addition to the top abstracts selected by our steering committee, the Multiple Myeloma Hub would like to highlight some key region-specific abstracts in the field of multiple myeloma and plasma cell dyscrasias.

Latin America

P954

Multiple myeloma in Latin America cancer registry: The MYLACRE study

Vania Hungria

P963

Extramedullary multiple myeloma: Clinical characteristics, impact, and outcomes in a cohort of patients in Mexico

Amaya Llorente Chávez

Asia Pacific

P952

Prognostic significance of dynamic change of MAGE-C1/CT7 in multiple myeloma: Ten year experience from a single center

Xuelin Dou

P976

Real-world outcomes of patients with penta-exposed multiple myeloma who were treated with selinexor and dexamethasone: Korean multicenter retrospective analysis

Jun Ho Yi

PB2146

Characteristics and outcomes of COVID-19 in patients with plasma cell disorders during the first omicron wave in Beijing since December 2022: A retrospective study at a tertiary center

Xuelin Dou

Middle East and Africa

PB2081

Cytogenetics of multiple myeloma in Morocco

Yasmine Moutmir

PB2160

Multiple myeloma in the elderly: A monocentric experience of the hematology department of Monastir (Tunisia)

Bizid Inaam

Europe

P944

Real-world patient characteristics and survival outcomes of lenalidomide refractory vs. lenalidomide exposed RRMM patients in the HONEUR federated data network

Ivan Spicka

P958

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the UK, France, and Spain

Karthik Ramasamy

P981

Disease characteristics and treatment outcomes of myeloma patients <50 years of age: An analysis of the Balkan myeloma study group

Efstathios Kastritis

PB2137

Socio-demographic features and treatment patterns of multiple myeloma patients in Spain: an interim analysis of DORIANT study

Marta Grande

 

EHA 2023 top abstracts

To download this document, click below.

Download here

More about...
Auto-HSCTBelantamab mafodotinCAEL-101CARTITUDE-1Ciltacabtagene autoleucelEHAEHA 2023ElranatamabIdecabtagene vicleucelKarMMa-3LinvoseltamabMagnetisMM-3MASTERNewly diagnosed multiple myelomaPlasma cell dyscrasiasRelapsed/refractory multiple myelomaTalquetamabTeclistamab

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
28 votes - 3 days left ...

Related articles

Add bookmark

CARTITUDE-2 Cohort C: Efficacy and safety of cilta-cel in patients with relapsed/refractory MM

We summarize the latest efficacy and safety findings of cilta-cel in patients with progressive MM after non-cellular anti-BCMA immunotherapy from Cohort C...

May 25, 2023
Add bookmark

CARTITUDE-2 Cohort C: Efficacy and safety of cilta-cel in patients with relapsed/refractory MM

We summarize the latest efficacy and safety findings of cilta-cel in patients with progressive MM after...

May 25, 2023
Add bookmark

Infection incidence with CAR T-cell and bispecific antibody therapies

We summarize a presentation from the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop on infection incidence associated with CAR T-cell and bispecific antibody...

May 19, 2023
Add bookmark

Infection incidence with CAR T-cell and bispecific antibody therapies

We summarize a presentation from the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop on infection incidence...

May 19, 2023
Add bookmark

MRD-guided consolidation and treatment de-escalation: Results from the MASTER trial

Minimal/measurable residual disease (MRD) following primary treatment is prognostic of the long-term outcomes in patients with newly diagnosed multiple myeloma...

Feb 15, 2022
Add bookmark

MRD-guided consolidation and treatment de-escalation: Results from the MASTER trial

Minimal/measurable residual disease (MRD) following primary treatment is prognostic of the long-term outcomes in...

Feb 15, 2022

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox